Home Tools
Log in
Cart

c-Met/HGFR

c-Met, also called tyrosine-protein kinase Met or hepatocyte growth factor receptor (HGFR), is a protein that in humans is encoded by the MET gene. The protein possesses tyrosine kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor.MET is a single pass tyrosine kinase receptor essential for embryonic development, organogenesis and wound healing.
Cat. No. Product name CAS No. Purity Chemical Structure
T63313 Unecritinib 1418026-92-2 98%
Unecritinib (TQ-B3101) is a potent, orally active, highly potent, blood-brain barrier permeable and low toxic inhibitor of EGFR tyrosine kinase with antitumor ac...
T77437 Telisotuzumab 1781223-80-0 98%
Telisotuzumab(ABT-700) is a humanized recombinant antibody targeting the therapeutic hepatocyte growth factor receptor (MET) with high affinity for c-Met.Telisot...
T3512 S49076 HCl 1265966-31-1 98%
S49076 is an effective inhibitor of MET, AXL/MER, and FGFR1/2/3. S49076 potently blocked cellular phosphorylation of MET, AXL, and FGFRs and inhibited downstream...
T12417 PF-04217903 methanesulfonate 956906-93-7 98%
PF-04217903 methanesulfonate is a potent ATP-competitive inhibitor of c-Met kinase (Ki of 4.8 nM for human c-Met).
T10653 C-met-IN-1 2084836-84-8 98%
c-met-IN-1 is a potent and selective c-Met inhibitor (IC50: 1.1 nM) with antitumor activity.
T17184 Tyrosine kinase inhibitor 1021950-26-4 98%
Tyrosine kinase inhibitor is a tyrosine kinase inhibitor used in combination with fragmenting aromatic nitrogen compounds as antiproliferative agents.
T15383 Glesatinib hydrochloride 1123838-51-6 98%
Glesatinib hydrochloride is an orally active and potent dual inhibitor of MET/SMO. Glesatinib hydrochloride is also a tyrosine kinase inhibitor. It antagonizes P...
T10654 C-Met-IN-2 1635406-73-3 98%
c-Met-IN-2 is a selective and orally available c-Met inhibitor (IC50: 0.6 nM) with antitumor activity.
T12418 PF-04217903 phenolsulfonate 1159490-85-3 98%
PF-04217903 phenolsulfonate is a potent ATP-competitive inhibitor of c-Met kinase (Ki of 4.8 nM for human c-Met).
T15384 Glesatinib 936694-12-1 98%
Glesatinib is an orally active and potent dual inhibitor of MET/SMO. Glesatinib is also a tyrosine kinase inhibitor. It antagonizes P-glycoprotein mediated multi...
TN4474 Macrocarpal B 142698-60-0 98%
The intestinal absorption of M-A, Macrocarpal B, and Cy-C was passive diffusion as the dominating process and Cy-C was partly ATP-dependent.
T6117 Tivantinib 905854-02-6 98%
Tivantinib is an orally bioavailable small molecule inhibitor of c-Met with potential antineoplastic activity.
T2894 Norcantharidin 5442-12-6 98%
Norcantharidin is a synthetic anticancer compound which is a dual inhibitor for c-Met and EGFR in human colon cancers.
T8825 Capmatinib 2HCl.H2O 1865733-40-9 98%
Capmatinib 2HCl.H2O is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.
T25492 Hepln-13 64369-13-7 98%
Hepln-13 is a hepsin inhibitor that acts by hindering prostate cancer bone metastasis.
T5349 SCR-1481B1 1174161-86-4 98%
SCR-1481B1 has activity against cancers dependent on Met activation and also has activity against cancers as a VEGFR inhibitor
T3209 AMG-337 1173699-31-4 98%
AMG-337 is an effective and highly specific ATP-competitive MET kinase inhibitor. In enzymatic assays, AMG-337 inhibits MET kinase activity (IC50: < 5 nM).
T2419 BMS-794833 1174046-72-0 98%
BMS-794833 is a potent ATP competitive inhibitor of Met/VEGFR2; a prodrug of BMS-817378.
TQ0041 Ningetinib Tosylate 1394820-77-9 98%
Ningetinib Tosylate is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.
T1963 Capmatinib 1029712-80-8 98%
Capmatinib is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.
Unecritinib
T63313
Unecritinib (TQ-B3101) is a potent, orally active, highly potent, blood-brain barrier permeable and low toxic inhibitor of EGFR tyrosine kinase with antitumor ac...
Telisotuzumab
T77437
Telisotuzumab(ABT-700) is a humanized recombinant antibody targeting the therapeutic hepatocyte growth factor receptor (MET) with high affinity for c-Met.Telisot...
S49076 HCl
T3512
S49076 is an effective inhibitor of MET, AXL/MER, and FGFR1/2/3. S49076 potently blocked cellular phosphorylation of MET, AXL, and FGFRs and inhibited downstream...
PF-04217903 methanesulfonate
T12417
PF-04217903 methanesulfonate is a potent ATP-competitive inhibitor of c-Met kinase (Ki of 4.8 nM for human c-Met).
c-met-IN-1
T10653
c-met-IN-1 is a potent and selective c-Met inhibitor (IC50: 1.1 nM) with antitumor activity.
Tyrosine kinase inhibitor
T17184
Tyrosine kinase inhibitor is a tyrosine kinase inhibitor used in combination with fragmenting aromatic nitrogen compounds as antiproliferative agents.
Glesatinib hydrochloride
T15383
Glesatinib hydrochloride is an orally active and potent dual inhibitor of MET/SMO. Glesatinib hydrochloride is also a tyrosine kinase inhibitor. It antagonizes P...
c-Met-IN-2
T10654
c-Met-IN-2 is a selective and orally available c-Met inhibitor (IC50: 0.6 nM) with antitumor activity.
PF-04217903 phenolsulfonate
T12418
PF-04217903 phenolsulfonate is a potent ATP-competitive inhibitor of c-Met kinase (Ki of 4.8 nM for human c-Met).
Glesatinib
T15384
Glesatinib is an orally active and potent dual inhibitor of MET/SMO. Glesatinib is also a tyrosine kinase inhibitor. It antagonizes P-glycoprotein mediated multi...
Macrocarpal B
TN4474
The intestinal absorption of M-A, Macrocarpal B, and Cy-C was passive diffusion as the dominating process and Cy-C was partly ATP-dependent.
Tivantinib
T6117
Tivantinib is an orally bioavailable small molecule inhibitor of c-Met with potential antineoplastic activity.
Norcantharidin
T2894
Norcantharidin is a synthetic anticancer compound which is a dual inhibitor for c-Met and EGFR in human colon cancers.
Capmatinib 2HCl.H2O
T8825
Capmatinib 2HCl.H2O is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.
Hepln-13
T25492
Hepln-13 is a hepsin inhibitor that acts by hindering prostate cancer bone metastasis.
SCR-1481B1
T5349
SCR-1481B1 has activity against cancers dependent on Met activation and also has activity against cancers as a VEGFR inhibitor
AMG-337
T3209
AMG-337 is an effective and highly specific ATP-competitive MET kinase inhibitor. In enzymatic assays, AMG-337 inhibits MET kinase activity (IC50: < 5 nM).
BMS-794833
T2419
BMS-794833 is a potent ATP competitive inhibitor of Met/VEGFR2; a prodrug of BMS-817378.
Ningetinib Tosylate
TQ0041
Ningetinib Tosylate is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.
Capmatinib
T1963
Capmatinib is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.
1 2 3 4 5